RhumbLine Advisers’s Amedisys AMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-90,116
| Closed | -$8.87M | – | 4122 |
|
|
2025
Q2 | $8.87M | Sell |
90,116
-1,262
| -1% | -$119K | 0.01% | 1110 |
|
|
2025
Q1 | $8.46M | Buy |
91,378
+80
| +0.1% | +$7.38K | 0.01% | 1093 |
|
|
2024
Q4 | $8.29M | Buy |
91,298
+1,412
| +2% | +$130K | 0.01% | 1152 |
|
|
2024
Q3 | $8.67M | Buy |
89,886
+2,125
| +2% | +$207K | 0.01% | 1141 |
|
|
2024
Q2 | $8.06M | Sell |
87,761
-2,452
| -3% | -$228K | 0.01% | 1136 |
|
|
2024
Q1 | $8.31M | Sell |
90,213
-3,628
| -4% | -$340K | 0.01% | 1142 |
|
|
2023
Q4 | $8.92M | Sell |
93,841
-4,258
| -4% | -$398K | 0.01% | 1118 |
|
|
2023
Q3 | $9.16M | Sell |
98,099
-1,386
| -1% | -$128K | 0.01% | 1026 |
|
|
2023
Q2 | $9.1M | Buy |
99,485
+2,456
| +3% | +$201K | 0.01% | 1057 |
|
|
2023
Q1 | $7.14M | Sell |
97,029
-999
| -1% | -$86.4K | 0.01% | 1136 |
|
|
2022
Q4 | $8.19M | Buy |
98,028
+3,408
| +4% | +$307K | 0.01% | 1034 |
|
|
2022
Q3 | $9.16M | Buy |
94,620
+1,970
| +2% | +$235K | 0.01% | 930 |
|
|
2022
Q2 | $9.74M | Buy |
92,650
+4,665
| +5% | +$596K | 0.01% | 907 |
|
|
2022
Q1 | $15.2M | Sell |
87,985
-157
| -0.2% | -$23.5K | 0.02% | 721 |
|
|
2021
Q4 | $14.3M | Buy |
88,142
+5,145
| +6% | +$827K | 0.02% | 779 |
|
|
2021
Q3 | $12.4M | Sell |
82,997
-540
| -0.6% | -$112K | 0.02% | 844 |
|
|
2021
Q2 | $20.5M | Sell |
83,537
-2,113
| -2% | -$554K | 0.03% | 590 |
|
|
2021
Q1 | $22.7M | Sell |
85,650
-1,648
| -2% | -$465K | 0.03% | 528 |
|
|
2020
Q4 | $25.6M | Sell |
87,298
-1,429
| -2% | -$366K | 0.04% | 451 |
|
|
2020
Q3 | $21M | Sell |
88,727
-3,044
| -3% | -$692K | 0.03% | 452 |
|
|
2020
Q2 | $18.2M | Sell |
91,771
-5,969
| -6% | -$1.11M | 0.03% | 483 |
|
|
2020
Q1 | $17.9M | Sell |
97,740
-685
| -0.7% | -$122K | 0.04% | 422 |
|
|
2019
Q4 | $16.4M | Buy |
98,425
+1,365
| +1% | +$203K | 0.03% | 569 |
|
|
2019
Q3 | $12.7M | Buy |
97,060
+4,184
| +5% | +$545K | 0.02% | 654 |
|
|
2019
Q2 | $11.3M | Buy |
92,876
+5,145
| +6% | +$611K | 0.02% | 714 |
|
|
2019
Q1 | $10.8M | Buy |
87,731
+8,673
| +11% | +$1.09M | 0.02% | 722 |
|
|
2018
Q4 | $9.26M | Buy |
79,058
+13,414
| +20% | +$1.58M | 0.02% | 755 |
|
|
2018
Q3 | $8.2M | Sell |
65,644
-3,063
| -4% | -$338K | 0.02% | 789 |
|
|
2018
Q2 | $5.87M | Buy |
68,707
+2,077
| +3% | +$153K | 0.01% | 996 |
|
|
2018
Q1 | $4.02M | Buy |
66,630
+1,621
| +2% | +$92.3K | 0.01% | 1189 |
|
|
2017
Q4 | $3.43M | Buy |
65,009
+9,058
| +16% | +$477K | 0.01% | 1303 |
|
|
2017
Q3 | $3.13M | Buy |
55,951
+1,765
| +3% | +$93.3K | 0.01% | 1327 |
|
|
2017
Q2 | $3.4M | Sell |
54,186
-619
| -1% | -$36K | 0.01% | 1236 |
|
|
2017
Q1 | $2.8M | Buy |
54,805
+14,942
| +37% | +$713K | 0.01% | 1358 |
|
|
2016
Q4 | $1.7M | Buy |
39,863
+1,607
| +4% | +$68.3K | ﹤0.01% | 1544 |
|
|
2016
Q3 | $1.81M | Buy |
38,256
+2,265
| +6% | +$113K | 0.01% | 1468 |
|
|
2016
Q2 | $1.82M | Sell |
35,991
-2,858
| -7% | -$144K | 0.01% | 1405 |
|
|
2016
Q1 | $1.88M | Buy |
38,849
+1,350
| +4% | +$52.1K | 0.01% | 1423 |
|
|
2015
Q4 | $1.47M | Buy |
37,499
+1,875
| +5% | +$75K | ﹤0.01% | 1546 |
|
|
2015
Q3 | $1.35M | Buy |
35,624
+14
| +0% | +$590 | ﹤0.01% | 1595 |
|
|
2015
Q2 | $1.42M | Sell |
35,610
-9,110
| -20% | -$284K | ﹤0.01% | 1649 |
|
|
2015
Q1 | $1.2M | Buy |
44,720
+1,700
| +4% | +$48K | ﹤0.01% | 1745 |
|
|
2014
Q4 | $1.26M | Buy |
43,020
+430
| +1% | +$10.6K | ﹤0.01% | 1647 |
|
|
2014
Q3 | $859K | Buy |
42,590
+455
| +1% | +$8.78K | ﹤0.01% | 1858 |
|
|
2014
Q2 | $705K | Sell |
42,135
-4,992
| -11% | -$70.7K | ﹤0.01% | 2058 |
|
|
2014
Q1 | $702K | Sell |
47,127
-1,340
| -3% | -$20.6K | ﹤0.01% | 2015 |
|
|
2013
Q4 | $709K | Sell |
48,467
-3,200
| -6% | -$51.5K | ﹤0.01% | 2036 |
|
|
2013
Q3 | $890K | Sell |
51,667
-1,041
| -2% | -$15.4K | ﹤0.01% | 1851 |
|
|
2013
Q2 | $612K | Buy |
+52,708
| New | +$604K | ﹤0.01% | 2108 |
|
Other funds holding AMED
IA
MCI
HNB
RhumbLine Advisers's AMED Position: Q3 2025 in Review
RhumbLine Advisers sold out of Amedisys (AMED) in Q3 2025, closing a stake of 90,116 shares — an estimated $8.87M sold.
RhumbLine Advisers first reported a position in AMED in Q2 2013 and held it in 49 quarters. The position peaked at $25.6M in Q4 2020. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.
- RhumbLine Advisers reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
- RhumbLine Advisers sold 90,116 Amedisys shares in Q3 2025, an estimated $8.87M.
- RhumbLine Advisers first reported a position in Amedisys in Q2 2013 and held it in 49 quarters.
- RhumbLine Advisers's Amedisys position peaked at $25.6M in Q4 2020.
- 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.
Based on RhumbLine Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.